Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLESTAR: poseltinib plus lenalidomide consolidation after CAR-T remission in DLBCL
KCT0012890Phase 2Not yet recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poseltinib and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Seoul National University Bundang Hospital. Primary endpoint: 12-month progression-free survival rate. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
poseltiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0012890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012890.